CoreRx Completes Acquisition of Societal CDMO

• CoreRx has successfully acquired Societal CDMO, with the tender offer expiring on April 5, 2024.

• Approximately 92.8% of the issued and outstanding shares were validly tendered and will be promptly paid for.

• Following the acquisition, Societal CDMO has become a wholly-owned subsidiary of CoreRx.

Pharmaceutical company CoreRx has completed its acquisition of Societal CDMO. The acquisition was achieved through a tender offer to purchase all issued and outstanding shares of Societal CDMO at a price of $1.10 per share. The tender offer expired as scheduled on April 5, 2024, and was not extended.

The tender offer expired on April 5, 2024, Eastern Time, and was not further extended. The acquisition took place under Section 321(f) of the Pennsylvania Business Corporation Law of 1988.

Following the completion of the tender offer, CoreRx completed the acquisition of Societal CDMO through a second-step merger. As a result, Societal CDMO became a wholly-owned subsidiary of CoreRx. The common stock of Societal CDMO will be delisted from the Nasdaq Capital Market.